RxDoctor Payments Data

Jessica Duddleston, MD

Ophthalmology · Mountain Brk, ALNPI 1295226140

Payments from drug & device makers

$3,018in general payments, 2019–2025

Across 56 payments — averaging $53.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$1K
  • NEW World Medical,inc.$657
  • AbbVie$284
  • Oyster Point Pharma, Inc.$227
  • Glaukos Corporation$168
  • Sight Sciences, Inc.$154
  • plus $308 from 6 others

What the payments were for

  • Food & beverage$3,018100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,018 in reported general payments places this provider in the 65th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$131,610
Medicare patients
337
Services billed
1,015

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast15$11,656
RestasisCyclosporine13$11,193
Cyclosporine11$10,079
Prednisolone Acetate106$4,830
Latanoprost362$4,473
Travoprost17$3,712
RocklatanNetarsudil Mesylat/Latanoprost11$3,524
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol21$3,320
MoxifloxacinMoxifloxacin Hcl89$3,236
Timolol Maleate75$2,126
Ketorolac Tromethamine101$2,021
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat88$1,450
Brimonidine Tartrate20$511
ErythromycinErythromycin Base18$218

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra$103$11,65615 claims
AbbVieRestasis$284$11,19313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Mountain Brk

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →